NCT06229912View on ClinicalTrials.gov

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions

LeukemiaHOX Gene

Interventions

DRUG

Revumenib

Given by PO

Trial Locations (2)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Syndax Pharmaceuticals

All Listed Sponsors

collaborator

Syndax Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER